Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women

Journal of Clinical Endocrinology and Metabolism

Volumn 81, Issue 1, 1996, Pages 37-43

  Raisz, Lawrence G ^a   Wiita, Brinda ^b   Artis, Althea ^b   Bowen, Angela ^c   Schwartz, Sherwyn ^d   Trahiotis, Margaret ^a   Shoukri, Kamal ^a   Smith, JoAnne ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b Solvay Pharmaceuticals Inc   (Netherlands)

^c Middleton Foundation   (United States)

^d Diabetes and Glandular Disease Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; CONJUGATED ESTROGEN; DEOXYPYRIDINOLINE; ESTERIFIED ESTROGEN; ESTRATEST; ESTROGEN DERIVATIVE; HIGH DENSITY LIPOPROTEIN; HYDROXYPROLINE; LOW DENSITY LIPOPROTEIN; MEDROXYPROGESTERONE ACETATE; METHYLTESTOSTERONE; OSTEOCALCIN; PROCOLLAGEN; PYRIDINE DERIVATIVE; PYRIDINOLINE; SEX HORMONE BINDING GLOBULIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE TURNOVER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEADACHE; HUMAN; LIPOPROTEIN BLOOD LEVEL; MASTALGIA; ORAL DRUG ADMINISTRATION; OSSIFICATION; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; URINARY EXCRETION;

AGED; ANDROGENS; BONE DEVELOPMENT; BONE RESORPTION; CHOLESTEROL; DRUG THERAPY, COMBINATION; ESTROGENS; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE;

EQUIDAE;

EID: 0030065996     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.81.1.37     Document Type: Article

References (56)

1. Lufkin EG, Wahner HW, O'Fallon WM, et al. 1992 Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med. 117:1-9.
2. Raisz LG, Shoukri KC. 1993 Pathogenesis of osteoporosis. In: Mundy GR, Martin TJ, eds. Physiology and pharmacology of bone. Heidelberg: Springer-Verlag; 299-323.
3. Colvard DS, Eriksen EF, Keeting PE, et al. 1989 Identification of androgen receptors in normal human osteoblast-like cells. Proc Natl Acad Sci USA. 86:854-857.
4. 1(I)-procollagen and transforming growth factor-β steady state messenger ribonucleic acid levels in human osteoblast-like osteosarcoma cells. Endocrinology. 128:2723-2728.
5. Orwoll ES, Stribrska L, Ramsey EE, Keenan EJ. 1991 Androgen receptors in osteoblast-like cell lines. Calcif Tissue Int. 49:183-187.
6. Wild RA, Buchanan JR, Myers C, Demers LM. 1987 Declining adrenal androgens: an association with bone loss in aging women. Proc Soc Exp Biol Med. 186:355-360.
7. Brody S, Carlström K, Lagrelius A, Lunell NO, Möllerström G, Pousette Å. 1987 Serum sex hormone binding globulin (SHBG), testosterone/SHBG index, endometrial pathology and bone mineral density in postmenopausal women. Acta Obstet Gynecol Scand. 66:357-360.
8. Buchanan JR, Hospodar P, Myers C, Leuenberger P, Demers LM. 1988 Effect of excess endogenous androgens on bone density in young women. J Clin Endocrinol Metab. 67:937-943.
9. Steinberg KK, FreniTitulaer LW, DePuey EG, et al. 1988 Sex steroids and bone density in premenopausal and perimenopausal women. J Clin Endocrinol Metab. 69:533-539.
10. Dixon JE, Rodin A, Murphy B, Chapman MG, Fogelnian I. 1989 Bone mass in hirsute women with androgen excess. Clin Endocrinol (Oxf). 30:271-277.
11. Prezelj J, Kocijancic A. 1993 Antiandrogen treatment with spironolactone and linestrenol decreases bone mineral density in eumenorrhoeic women with androgen excess. Horm Metab Res. 26:46-47.
12. Jassal SK, Barrett-Connor E, Edelstein SL. 1995 Low bioavailable testosterone levels predict future height loss in postmenopausal women. J Bone Miner Res. 10:650-654.
13. Murphy S, Khaw K, Cassidy, et al. 1993 Sex hormones and bone mineral density in elderly men. Bone Miner. 20:133-140.
14. Longcope C, Baker RS, Hui SL, et al. 1984 Androgen and estrogen dynamics in women with vertebral crush fractures. Maturitas. 6:309-318.
15. Davidson BJ, Ross RK, Paganini-Hill A, et al. 1982 Total and free estrogens and androgens in postmenopausal women with hip fractures. J Clin Endocrinol Metab. 54:115-120.
16. Devogelaer JP, De Cooman S, de Deuxchaisnes CN. 1992 Low bone mass in hypogonadal males. Effect of testosterone substitution therapy, a densitometric study. Maturitas. 15:17-23.
17. Riggs BL, Jowsey J, Goldsmith RS, et al. 1972 Short- and long-term effects of estrogen and synthetic anabolic hormone in postmenopausal osteoporosis. J Clin Invest. 51:1659-1663.
18. Chesnut CH, Iven JL, Gruber HE, et al. 1983 Stanozolol in postmenopausal osteoporosis: therapeutic efficacy and possible mechanisms of action. Metabolism. 32:571-580.
19. Need AG, Horowitz M, Bridges A, et al. 1989 Effects of nandrolone decanoate and antiresorptive therapy on vertebral density in osteoporotic postmenopausal women. Arch Intern Med. 149:57-60.
20. Passen M, Pedrazzoni M, Pioli G, et al. 1993 Effects of nandrolone decanoate on bone mass in established osteoporosis. Maturitas. 17:211-219.
21. Savvas M, Studd JWW, Norman S, et al. 1992 Increase in bone mass after one year of percutaneous oestradiol and testosterone implants in post-menopausal women who have previously received long-term oral oestrogens. Br J Obstet Gynaecol. 99:757-760.
22. Taylor WN, Alanis C. 1992 Triple sex steroid replacement therapy for osteoporosis after surgical menopause. J Neurol Orthop Med Surg. 13:16-19.
23. Erdtsieck RJ, Pols HAP, Van Kuijk C, et al. 1994 Course of bone mass during and after hormonal replacement therapy with and without addition of nandrolone decanoate. J Bone Miner Res. 9:277-283.
24. Pilbeam CC, Raisz LG. 1990 Effects of androgens on parathyroid hormone and interleukin-1-stimulated prostaglandin production in cultured neonatal mouse calvariae. J Bone Miner Res. 5:1183-1188.
25. Vanderschueren D, Van Herck E, Suiker AMH, Visser WJ, Schot LPC, Bouillon R. 1992 Bone and mineral metabolism in aged male rats: short and long term effects of androgen deficiency. Endocrinology. 130:2906-2916.
26. Vanderschueren D, Van Herck E, Suiker AMH, et al. Bone and mineral metabolism in the androgen-resistant (testicular feminized) male rat. J Bone Miner Res. 8:801-809.
27. Vanderschueren D, Van Herck E, Geusens P, et al. 1994 Androgen resistance and deficiency have different effects on the growing skeleton of the rat. Calcif Tissue Int. 55:198-203.
28. Vanderschueren D, Bouillon R. 1995 Androgens and bone. Calcif Tissue Int. 56:341-346.
29. Hasling C, Eriksen EF, Melkko J, et al. 1991 Effects of a combined estrogen-gestagen regimen on serum levels of the carboxy-terminal propeptide of human type I procollagen in osteoporosis. J Bone Miner Res. 6:1295-1300.
30. Seibel MJ, Cosman F, Shen V, et al. 1993 Urinary hydroxypyridinium crosslinks of collagen as markers of bone resorption and estrogen efficacy in postmenopausal osteoporosis. J Bone Miner Res. 8:881-90.
31. Prestwood KM, Pilbeam CC, Burleson JA, et al. 1994 The short term effects of conjugated estrogen on bone turnover in older women. J Clin Endocrinol Metab. 79:366-371.
32. Baran DT, Bergfeld MA, Teitelbaum SL, Avioli LV. 1978 Effect of testosterone therapy on bone formation in an osteoporotic hypogonadal male. Calcif Tissue Res. 26:103-106.
33. Isaia G, Mussetta M, Pecchio F, et al. 1992 Effect of testosterone on bone in hypogonadal males. Muturitas. 15:47-51.
34. Adashi EY. 1994 The climacteric ovary as a functional gonadotropin-driven androgen-producing gland. Fertil Steril. 62:20-27.
35. Charles P, Hasling C, Risteli L, Mosekilde L, Eriksen EF. 1992 Assessment of bone formation by biochemical markers in metabolic bone disease-separation between osteoblastic activity at the cell and tissue level. Calcif Tissue Int. 51:406-411.
36. Eriksen EF, Charles P, Melsen F, Mosekilde L, Risteli L, Risteli J. 1993 Serum markers of type-I collagen formation and degradation in metabolic bone disease-correlation with bone histomorphometry. J Bone Miner Res. 8:127-132.
37. Delmas PD. 1993 Biochemical markers of bone turnover. J Bone Miner Res. 8(Suppl 2):S549-S56.
38. Parviainen M, Kuronen I, Kokko H, Lakaniemi M, Savolainen K, Mononen I. 1994 Two-site enzyme immunoassay for measuring intact human osteocalcin in serum. J Bone Miner Res. 9:347-354.
39. Hassager C, Jensen LT, Pødenphant, et al. 1990 Collagen synthesis in postmenopausal women during therapy with anabolic steroid or female sex hormones. Metabolism. 39:1167-1169.
40. Kuppennan HS, Wetchler BB, Blatt MHG. 1959 Contemporary therapy of the menopausal syndrome. JAMA. 171:1627-1637.
41. Watts NB, Notelovitz M, Timmons MC, Addison WA, Wiita B, Downey LJ. 1995 Comparison of oral estrogens and estrogens plus androgen on bone mineral density, menopausal symptoms, and lipid-lipoprotein profiles in surgical menopause. Obstet Gynecol. 85:529-537.
42. 2-terminal propeptides of types I and III procollagen is a physiological function of the scavenger receptor in liver endothelial cells. J Exp Med. 179: 405-412.
43. Garnero P, Grimaux M, Seguin P, Delmas PD. 1994 Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro. J Bone Miner Res. 9:255-264.
44. Sherwin BB, Gelfand MM. 1985 Differential symptom response to parenteral estrogen and/or androgen administration in the surgical menopause. Am J Obstet Gynecol. 151:153-160.
45. Bancroft J, Sanders D, Davidson D, Warner P. 1983 Mood, sexuality, hormones and the menstrual cycle. Sexuality and the role of androges. Psychosom Med. 45:509-516.
46. Häkkinen K, Pakarinen A. 1993 Muscle strength and serum testosterone, cortisol and SHBG concentrations in middle-aged and elderly men and women. Acta Physiol Scand 148:199-207.
47. van Hemert AM, Birkenhager JC, De Jong FH. 1989 Sex hormone binding globulin in postmenopausal women: a predictor of osteoporosis superior to endogenous oestrogens. Clin Endocrinol (Oxf). 31:499-509.
48. Hickock LR, Toomey C, Speroff L. 1993 A comparison of esterified estrogens with and without methyltestosterone: effects on endometrial histology and serum lipoproteins in postmenopausal women. Obstet Gynecol. 82:919-924.
49. Writing Group for the PEPI Trial. 1995 Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA. 273:199-208.
50. Hulley SB, Rosenman RH, Bawol RD, et al. 1980 Epidemiology as a guide to clinical decisions. N Engl J Med. 302:1383-1389.
51. Lapidus L, Bengtsson C, Lindquist O, et al. 1985 Triglycerides-main lipid risk factor for cardiovascular disease in women? Acta Med Scand. 217:481-489.
52. LaRosa JC. 1995 Has HRT come of age? Lancet. 345:76-77.
53. Levine GN, Keaney Jr JF, Vita JA. 1995 Cholesterol reduction in cardiovascular disease. N Engl J Med. 332:512-521.
54. Honore, EK, Williams JK, Adams MR, Ackerman DM, Wagner JD. Methyltestosterone does not diminish the beneficial affects of estrogen replacement therapy on vascular reactivity in cynomolgus monkeys. Menopause. In Press.
55. Dempsker DW, Cosman F, Parisien M, Shen V, Lindsay R. 1993 Anabolic actions of parathyroid hormone on bone. Endocr Rev. 14:690-709.
56. Vermeulen A. 1975 The hormonal activity of the postmenopausal ovary. J Clin Endocrinol Metab. 40:247-252.